Status:
COMPLETED
BMS-582664 in Combination With Erbitux in Patients With Advanced Gastrointestinal Malignancies
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664 in combination with full dose erbitux in patients with advanced colorectal cancer w...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy
- Feeling well other than cancer diagnosis (ie lab work, no infection, etc)
- Available tumor tissue sample from prior surgery
- Measurable disease on scans
- 4-6 weeks since prior therapy and recovered from the effects of prior therapy
- Men and women, ages 18 and above
- Women must not be pregnant or breastfeeding
Exclusion
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00207051
Start Date
January 1 2006
End Date
December 1 2008
Last Update
January 25 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Usc/Norris Comprehensive Cancer Center
Los Angeles, California, United States, 90033
2
Georgetn Univ Lombardi Can Ctr
Washington D.C., District of Columbia, United States, 20007
3
University Of Miami Miller School Of Medicine
Miami, Florida, United States, 33010
4
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612